Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 4/20 | 0.59 |
| ▸ | PTGES | O14684 | 3/20 | 0.59 |
| ▸ | PPARG | P37231 | 2/20 | 0.59 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.56 |
| ▸ | CES2 | O00748 | 3/20 | 0.51 |
| ▸ | CES1 | P23141 | 3/20 | 0.51 |
| ▸ | APEX1 | P27695 | 3/20 | 0.50 |
| ▸ | RECQL | P46063 | 1/20 | 0.50 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | ELANE | P08246 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL524131 | 1.00 | ALOX5 (0.59) | ALOX5PTGESPPARGLMNATDP1 | |
| SCHEMBL524132 | 1.00 | ALOX5 (0.59) | ALOX5PTGESPPARGLMNATDP1 | |
| SCHEMBL8702152 | 1.00 | ALOX5 (0.59) | ALOX5PTGESPPARGLMNATDP1 | |
| SCHEMBL28271475 | 0.95 | LMNA (0.66) | ALOX5PTGESPPARGLMNATDP1 | |
| SCHEMBL17629136 | 0.95 | LMNA (0.66) | ALOX5PTGESPPARGLMNATDP1 | |
| SCHEMBL17629135 | 0.95 | LMNA (0.66) | ALOX5PTGESPPARGLMNATDP1 | |
| SCHEMBL489897 | 0.93 | TDP1 (0.67) | ALOX5PTGESPPARGLMNATDP1 | |
| SCHEMBL6437828 | 0.93 | TDP1 (0.67) | ALOX5PTGESPPARGLMNATDP1 | |
| SCHEMBL3250732 | 0.93 | TDP1 (0.67) | ALOX5PTGESPPARGLMNATDP1 | |
| SCHEMBL5467260 | 0.93 | TDP1 (0.67) | ALOX5PTGESPPARGLMNATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2303902-B1 | BIS(PERFLUORALKYL)PHOSPHINOUS ACIDS AND DERIVATES AND USE THEREOF | MERCK PATENT GMBH (DE) | 2013-08-21 | — | — | EP | disclosed |
| US-20110124873-A1 | Bis(perfluoralkyl)phosphinous acids and derivatives and use thereof | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2011-05-26 | — | — | US | disclosed |
| WO-1998049128-A1 | PROCESS FOR PREPARING A (HETERO)AROMATIC OLEFIN | DSM N.V. (NL) | 1998-11-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110124873-A1 | Bis(perfluoralkyl)phosphinous acids and derivatives and use thereof | PFKFB3, PFAS, PFKFB2 | ALOX5 590/4885PTGES 1748/4885PPARG 192/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.